PGK1 (Phosphoglycerate Kinase 1)

We developed and validated a robust CCRG signature that effectively predicts prognosis, immune contexture, and therapeutic response in breast cancer. This signature offers novel insights into metabolic immunosuppression and provides a potential tool for risk stratification and personalized treatment strategies.

Spatially mapping 2H-lactate production from [6,6-2H]-glucose allows visualization of the metabolically active tumor lesion and provides an early readout of response to standard of care and targeted therapy that precedes extended survival and reflects pharmacodynamic alterations in tumor tissues in preclinical DMG models in vivo at clinical field strength (3 T). Overall, we have identified an H3K27M-lactate-NME1 axis that drives DMG proliferation and facilitates noninvasive in vivo metabolic imaging of DMGs.

The index related to TTK appears to be a valuable biomarker for effectively assessing survival and forecasting the success of therapy in patients with BRCA. This risk metric can enable timely and targeted early interventions for patients, thus promoting advancements in personalized medicine and enhancing the research in precise immuno-oncology.

Based on EPIC-0502-driven HIF1α degradation that overcomes BEV resistance and synergizes with TMZ, we propose the novel VITA-GBM regimen comprising: Vascular targeting (BEV), Inhibition of hypoxia signaling (EPIC-0502), TMZ chemotherapy, and Alignment of synergistic mechanisms. This strategy enhances the efficacy of first-line therapies and provides a promising approach to improve overall survival in GBM patients.

Pharmacological inhibition of acetylation attenuated PRAS40-mediated CRC stemness and colorectal carcinogenesis. Collectively, our findings uncover a novel PRAS40/PGK1 regulatory axis that promotes CRC stemness and tumorigenesis through enhanced glycolysis, suggesting potential therapeutic strategies targeting this axis for CRC treatment.

In vivo experiments suggested that emodin inhibited colon cancer tumor growth, as well as NAT10 and PGK1 expression. In conclusion, we demonstrated that emodin inhibited tumor growth of colon cancer by suppressing glycolysis in tumor cells through inhibiting NAT10-mediated ac4C modification of PGK1, indicating that emodin is an effective medicine for treatment of colon cancer.

The present study confirmed that pachymic acid played an inhibitory role in the proliferation and invasion of colon cancer by intervening in the process of glycolysis. PPARγ was identified as the primary target of pachymic acid in regulating the glucose metabolism in colon cancer.

This study classified BC by mRNAsi-related genes and established corresponding risk models. The findings of the present study propose a novel classification tool based on stem cell characteristics, which has the potential to be employed for prognostic stratification in BC patients and to offer guidance for developing personalised treatment strategies.

This integrative molecular and phenotypic profiling of blood-derived components identified potentially distinct molecular signatures, such as overexpression of IL12, ANGPT1 downregulation and HIF1A downregulation, in the literature described as linked to the patient's beneficial prognosis. These findings suggest that advanced liquid biopsy techniques may provide complementary insights into prognostic biomarkers and therapeutic targets in HGSOC.

Collectively, these findings establish ERCC1-iASPP as a bifunctional RNA with both protein-coding and non-coding regulatory roles that cooperatively promote B[a]P-induced lung tumorigenesis. This study highlights ERCC1-iASPP as a potential diagnostic and therapeutic target in smoking-related lung cancer.

Second- and third-line TKIs, such as sunitinib and regorafenib, provide limited benefits, highlighting the urgent need to address resistance mechanisms. These findings uncover a TGF-β1/CCN2/Rack1/PGK1 mechanism linking CAF-mediated metabolic reprogramming to imatinib resistance in GISTs. Targeting CAF-GIST interactions and key metabolic pathways presents a promising therapeutic strategy.